Eylea injections effective when other treatments for wet AMD have failed

A recent study conducted at the University of Iowa revealed that macular degeneration patients benefited from bimonthly injections of Eylea when monthly injections of Avastin or Lucentis failed. The injections are used for patients dealing with the wet form of macular degneration. Thirty-one patients in the study saw a reduction in fluid within their eyes after three months of treatment with Eylea. In addition, with the Eylea treatments being administered bimonthly as opposed to monthly with the other medications, there is a cost and time savings as well. Patients can become resistant to Lucentis and Avastin which results in the leaking of the blood vessels at the back of the eye, which causes the fluid build-up and vision loss. Eylea now provides another option for doctors when these primary treatment options fail.*